Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

7.5

2026

Interim report Q1'26

20.8

2026

Interim report Q2'26

5.11

2026

Interim report Q3'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press releaseyesterday

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)

Regulatory press release5/4/2026, 1:19 PM

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation

Press release4/27/2026, 5:07 AM

BioStock: Zelluna entering the clinic with promising TCR-NK therapy

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/23/2026, 7:37 AM

Zelluna ASA – Annual General Meeting held on April 23, 2026

Regulatory press release4/8/2026, 9:25 AM

Zelluna ASA - Disclosure of voting rights of Annual General Meeting

Regulatory press release4/8/2026, 9:25 AM

Zelluna ASA – Disclosure of voting rights of Annual General Meeting

Regulatory press release3/27/2026, 9:01 AM

Zelluna ASA – Mandatory notification of trade

Regulatory press release3/26/2026, 2:28 PM

ZLNA: Zelluna to host Capital Markets Update 2026

Regulatory press release3/26/2026, 2:28 PM

Zelluna to host Capital Markets Update 2026

Regulatory press release3/26/2026, 7:56 AM

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Regulatory press release3/25/2026, 6:00 AM

Zelluna ASA [ZLNA]: Annual Report 2025

Regulatory press release3/9/2026, 7:00 AM

ZLNA: Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Regulatory press release3/9/2026, 7:00 AM

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering

Regulatory press release2/20/2026, 1:30 PM

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Regulatory press release2/12/2026, 6:00 AM

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission

Regulatory press release2/11/2026, 7:00 AM

ZLNA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Regulatory press release2/11/2026, 7:00 AM

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Regulatory press release2/5/2026, 12:30 PM

Zelluna ASA - Grant of Share Options

Regulatory press release2/5/2026, 8:30 AM

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Regulatory press release2/3/2026, 7:00 AM

ZLNA: Zelluna promotes Emilie Gauthy to Chief Technology Officer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.